Hemogenyx Pharmaceuticals plc , a clinical-stage biopharmaceutical company, has successfully developed a clinical-grade assay to measure FLT3 protein expression in acute myeloid leukemia (AML) cells. This assay is essential for accurately identifying and selecting patients for the upcoming Phase I clinical trials of the company’s HEMO-CAR-T product candidate. These trials are set to begin shortly at MD Anderson Cancer Center, a globally renowned cancer research and treatment facility, with plans to expand to the University of Pennsylvania Medical Center.
Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals, emphasized the significance of this achievement, stating that the FLT3 assay is a major milestone in advancing their HEMO-CAR-T product into clinical trials. By enabling precise patient selection, this assay brings the company closer to offering a potentially life-saving treatment for AML patients. The Phase I trials are expected to commence imminently.